Your shopping cart is currently empty

DYRK2-IN-2 (Compound C17) is a selective inhibitor of DYRK2 with an IC50 of 40.3 nM. It exhibits significantly lower inhibitory activity against DYRK1A (IC50 = 1842 nM), DYRK1B (IC50 = 1335 nM), DYRK4 (IC50 = 1931 nM), DYRK3 (IC50 = 112 nM), and CLK proteins (IC50 = 540-6496 nM). DYRK2-IN-2 hinders the phosphorylation of Tau protein at Thr212 and demonstrates moderate cytotoxicity in HT22 cells. This compound is suitable for cancer research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | DYRK2-IN-2 (Compound C17) is a selective inhibitor of DYRK2 with an IC50 of 40.3 nM. It exhibits significantly lower inhibitory activity against DYRK1A (IC50 = 1842 nM), DYRK1B (IC50 = 1335 nM), DYRK4 (IC50 = 1931 nM), DYRK3 (IC50 = 112 nM), and CLK proteins (IC50 = 540-6496 nM). DYRK2-IN-2 hinders the phosphorylation of Tau protein at Thr212 and demonstrates moderate cytotoxicity in HT22 cells. This compound is suitable for cancer research. |
| Targets&IC50 | DYRK2:40.3 nM |
| Molecular Weight | 384.49 |
| Formula | C21H24N2O3S |
| Cas No. | 2416195-65-6 |
| Smiles | S(C[C@H]1CCNC1)C=2C3=C(N=C4C2C=C(OC)C=C4)C(CO)=CC(OC)=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.